How do the various mutations within the SARS-CoV-2 variants impact vaccine-induced immunity? The amazing @carolilucas@VogelsChantal@InciYildirim11 led this study with with help from others to tackle this question - using 18 CoV-2 variants. (1/n)
The study was designed to measure antibody and T cell immunity from people who were previously infected or not infected with SARS-CoV-2, before and after the 1st and 2nd doses of mRNA vaccines. Amazing effort by @InciYildirim11@SaadOmer3 (2/n)
Antibodies to the ancestral S1 and RBD were induced in both prev. infected and uninfected vaccinees. S/S1/RBD-specific IgG levels in response to vaccination were significantly higher in the previously infected compared to uninfected, as reported by others. (3/n)
Next, neutralization activity of antibodies induced by the mRNA vaccines was measured through 50% plaque-reduction neutralization (PRNT50). Despite faster and higher NAb responses in previously infected, similar NAb levels were achieved after 2nd dose in both groups. (4/n)
Notice that even though every vaccinated person generated anti-Spike IgG responses, 2 individuals failed to induce neutralizing Abs even after the 2 shots. We don’t know the underlying cause yet. (5/n)
Next we examined CD4 and CD8 T cell responses to spike and nucleocapsid proteins. mRNA vaccines induced robust activation of CD4 T cells in both previously infected and uninfected vaccinees against ancestral and P.1 spike. (6/n)
In contrast, we found reduced CD8 T cell responses to the P.1 variant spike antigen compared to ancestral spike. This may be related to the various mutations in P.1 spike protein. Mutations are discussed below. (7/n)
Note that other studies found no reduction in T cell responses to ancestral vs. VOC spike antigens in vaccinated people. Difference may be due to assays or hosts. (8/n)
How well do mRNA vaccine-induced antibodies work against variants? This is where having collaborators like @NathanGrubaugh is so powerful & enabling 💪🏼 He and his team have been surveying and studying every CoV2 variant in the community. (9/n)
We’re so lucky to tag team with @VogelsChantal in the Grubaugh lab who identified & provided 16/18 variants studied here. @carolilucas painstakingly propagated these variants and @VogelsChantal sequenced and validated each isolate. Spectacular team work! (10/n)
In addition to the spike, these variants have accumulated a number of mutations in other viral genes - important for viral transmission and immune evasion by the variants. This thread will only focus on the spike because that is what is used in mRNA vaccines. (11/n)
This 🏳️🌈 graph depicts the PRNT50 of antibodies induced in mRNA vaccinees against the ancestral vs. the 18 variants using authentic viral neutralization assays. You can see the various amino acid changes in the Spike correlating with reduction in NAb capacity. (12/n)
A linear mixed model by @jessroth95 revealed that 8 of the 11 key S gene mutations had significant negative effects on neutralization, and that L452R and E484K/Q had the greatest individual effects.(13/n)
ΔH69/V70 & E484K combination was synergistic (decreased neutralization more than the added effects; β=-0.182; p=0.005), L452R & P681R was antagonistic (decreased neutralization less than the added effects; β=0.228; p=0.003), and E484K & N501Y was neither (β=0.060; p=0.248). (14/)
Previously infected people had higher neutralization against variants than the uninfected in response to vaccination. Future vaccine boosters may help to overcome such NAb reduction observed for the variants with the L452R (B.1.617.2) or E484K & N501Y combo (P.1 , B.1.351). (15/)
Our study is a result of heroic efforts of many people, led by @carolilucas@VogelsChantal@InciYildirim11. Special thanks to Yale SARS-CoV-2 Genomic Surveillance Initiative, and the HCW volunteers for donating blood. @SaadOmer3@NathanGrubaugh & I co-supervised this work. (End)
Adding this awesome thread by @NathanGrubaugh to accompany mine above. Much more deeper dive into the viral genetics, mutation comparison, community spread, and implications on vaccination strategies.
Happy to share our latest work by @YYexin et al. on antibody-mediated control of endogenous retroviruses in mice. In the process, we found “natural antibodies” with broad reactivity against enveloped viruses. Here is how “panviral” antibodies work 🧵(1/)
Endogenous retroviruses (ERV) are remnants of genetic invaders that have integrated into our ancestors' genomes over millions of years. ERVs occupy ~8% of the human genome and are under constant host immune surveillance. (2/) nature.com/articles/nrg31… nature.com/articles/nrmic…
This work started over 7 years ago when @YYexin and @rebecca_treger began to examine why ERVs reactivate in certain mouse strains. Through many genetic crosses, we figured out that secreted IgM recruits complement to suppress infectious ERV from emerging. (3/)
This time, we developed a nasal booster vaccine for influenza viruses. In this preprint, @MiyuMoriyama et al. show that nasal boosters with unadjuvanted hemagglutinin protein induce sterilizing immunity in mice against flu. (1/) biorxiv.org/content/10.110…
This work builds on the Prime and Spike vaccine strategy by @tianyangmao @BenIsraelow et al. against COVID where mRNA vaccine followed by nasal booster with recombinant spike protein established local immunity, ⬇️ infection & transmission in rodents. (2/) science.org/doi/10.1126/sc…
For Prime and HA against flu, @MiyuMoriyama tested several different mRNA IM prime and nasal HA booster doses, followed by a homologous influenza virus challenge. Like Prime and Spike, no adjuvant is needed for the nasal booster due to preexisting immunity from Prime. (3/)
Much-needed data on the genetics of #longCOVID in a new preprint by @23andMeResearch - GWAS of #LongCOVID identified 3 loci pointing to immune and thrombo-inflammatory mechanisms 🔥 @ninaadsc 1) HLA-DQA1–HLA-DQB 2) ABO 3) BPTF–KPAN2–C17orf58
(1/) medrxiv.org/content/10.110…
Among research participants who reported acute SARS-CoV2 infection, 64,384 participants reported to have experienced Long COVID and 178,537 participants did not. Their analytical cohort consisted of 54,390 cases and 124,777 controls 👇🏼 (2/)
The top locus was in the HLA-DQA1–HLA-DQB intergenic region. Further analysis showed that HLA alleles HLA-DRB1*11:04, HLA-C*07:01, HLA-B*08:01, and HLA-DQA1*03:01 were significantly associated with #LongCOVID. In other words, crucial genes for T cell target detection! (3/)
Keynote talk by @MichaelPelusoMD. “#LongCovid is not a mystery anymore. Working with patients, I have optimism that we can figure this out.” #YaleCIISymposium
An excellent framework in thinking about the pathogenesis of #LongCovid
@MichaelPelusoMD
Sharing this scoping review on "Post-Acute sequelae of COVID-19 in pediatric patients within the United States" by @ChrisMillerDO - an amazing @YalePediatrics infectious diseases fellow focused on research and treatment of #longcovidkids (1/)
Key findings:
- Most pediatric LC patients were adolescents.
- ♀>♂️
- 80% of pediatric LC patients started with a mild initial infection.
- Asthma, atopy, allergic rhinitis (type 2 immune diseases), and obesity were frequently reported pre-existing conditions. (2/)
The most frequently reported symptoms in #longcovidkids are listed here (3/)
An important study by F. Eun-Hyung Lee's team shows that long lived plasma cells (the source of long-term circulating antibodies) fail to establish after mRNA vaccination (even combined with SARS-CoV-2 infection). 🧵 (1/) nature.com/articles/s4159…
The longevity of antibody-mediated protection against infectious diseases rely on whether or not the vaccines can establish long lived plasma cells (LLPC) in the bone marrow. They are the source of circulating antibodies for years to decades. (2/) nature.com/articles/s4159…
The study by Nguyen et al examined the long lived and short lived plasma cells in the bone marrow in people who received COVID mRNA vaccines, tetanus and flu vaccines at various time points . They found no LLPC (PopD) specific to COVID but found PopD against tetanus and flu. (3/)